p27/kip I expression in normal epithelium, benign and neoplastic breast lesions

被引:27
作者
De Paola, F
Vecci, AM
Granato, AM
Liverani, M
Monti, F
Innoceta, AM
Gianni, L
Saragoni, L
Ricci, M
Falcini, F
Amadori, D
Volpi, A
机构
[1] Morgagni Pierantoni Hosp, Dept Oncol, I-47100 Forli, Italy
[2] Ist Oncol Romagnolo, Forli, Italy
[3] Infermi Hosp, Dept Oncol, Rimini, Italy
[4] Infermi Hosp, Dept Clin Pathol, Rimini, Italy
关键词
p27/kip1; benign breast lesions; breast carcinoma;
D O I
10.1002/path.1011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The development of cancer in the breast and in other sites is a complex process requiring a number of different genetic and epigenetic alterations. The accumulation of the genetic changes is thought to underlie the progression from precancerous lesions to carcinomas. The expression of p27/kip1 protein, a cyclin-dependent kinase inhibitor, was investigated by immunohistochemistry in normal epithelial specimens, benign alterations, and malignant lesions of the breast. The number of p27/kap1-positive cells ranged from none to more than 98% in the overall series. Wide ranges of p27/kip1-positive cells were consistently observed within each histological category, but the median value progressively decreased in typical hyperplasia and fibroadenoma, with an even more marked reduction in malignant lesions, compared with normal epithelium. Moreover, the percentage of cells expressing p27/ktp1 in tumours was about three times lower in invasive than in in situ lesions and was inversely related to tumour size, but not to lymph node involvement. In conclusion, the degree to which p27 expression is altered in typical hyperplastic lesions and fibroadenomas indicates that the deregulation of p27 may occur very early on during breast cell transformation, but the usefulness of its determination to categorize subgroups of lesions at different risk of evolution remains somewhat doubtful. Copyright (C) 2001 John Wiley Sons, Ltd.
引用
收藏
页码:26 / 31
页数:6
相关论文
共 39 条
[1]   Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation [J].
Alessandrini, A ;
Chiaur, DS ;
Pagano, M .
LEUKEMIA, 1997, 11 (03) :342-345
[2]   ESTABLISHMENT AND CHARACTERIZATION OF A NEW CELL-LINE FROM PRIMARY HUMAN BREAST-CARCINOMA [J].
AMADORI, D ;
BERTONI, L ;
FLAMIGNI, A ;
SAVINI, S ;
DEGIOVANNI, C ;
CASANOVA, S ;
DEPAOLA, F ;
AMADORI, A ;
GIULOTTO, E ;
ZOLI, W .
BREAST CANCER RESEARCH AND TREATMENT, 1993, 28 (03) :251-260
[3]  
Bast RC, 1996, J CLIN ONCOL, V14, P2843
[4]   Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1 [J].
Cariou, S ;
Catzavelos, C ;
Slingerland, JM .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :29-41
[5]   A PROSPECTIVE-STUDY OF THE DEVELOPMENT OF BREAST-CANCER IN 16,692 WOMEN WITH BENIGN BREAST DISEASE [J].
CARTER, CL ;
CORLE, DK ;
MICOZZI, MS ;
SCHATZKIN, A ;
TAYLOR, PR .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1988, 128 (03) :467-477
[6]   Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer [J].
Catzavelos, C ;
Bhatacharya, N ;
Ung, YC ;
Wilson, JA ;
Roncari, L ;
Sandhu, C ;
Shaw, P ;
Yeger, H ;
MoravaProtzner, I ;
Kapusta, L ;
Franssen, E ;
Pritchard, KI ;
Slingerland, JM .
NATURE MEDICINE, 1997, 3 (02) :227-230
[7]  
Ciaparrone M, 1998, CANCER RES, V58, P114
[8]   Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation [J].
Durand, B ;
Gao, FB ;
Raff, M .
EMBO JOURNAL, 1997, 16 (02) :306-317
[9]   High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers [J].
Fredersdorf, S ;
Burns, J ;
Milne, AM ;
Packham, G ;
Fallis, L ;
Gillett, CE ;
Royds, JA ;
Peston, D ;
Hall, PA ;
Hanby, AM ;
Barnes, DM ;
Shousha, S ;
OHare, MJ ;
Lu, X .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (12) :6380-6385
[10]  
Gillett CE, 1999, J PATHOL, V187, P200, DOI 10.1002/(SICI)1096-9896(199901)187:2<200::AID-PATH228>3.0.CO